1995 EASD meetings. Immunology, insulin, amylin, obesity, retinopathy, and neuropathy.
作者信息
Bloomgarden Z T
出版信息
Diabetes Care. 1996 May;19(5):550-4. doi: 10.2337/diacare.19.5.550.
PMID:8732728
Abstract
摘要
相似文献
1
1995 EASD meetings. Immunology, insulin, amylin, obesity, retinopathy, and neuropathy.
Diabetes Care. 1996 May;19(5):550-4. doi: 10.2337/diacare.19.5.550.
2
The biological role of islet amyloid polypeptide (amylin) in diabetes: some recent results.胰岛淀粉样多肽（胰淀素）在糖尿病中的生物学作用：一些近期研究结果
Diabetologia. 1994 Feb;37(2):225-6.
3
New treatments of diabetes: the beta-amylin agonists.糖尿病的新疗法：β-淀粉样蛋白激动剂。
Ann Endocrinol (Paris). 2008 Apr;69(2):147-50. doi: 10.1016/j.ando.2008.02.015. Epub 2008 Apr 18.
4
Does amylin have a pathophysiological endocrine role in diabetes mellitus in man?胰岛淀粉样多肽在人类糖尿病中是否具有病理生理内分泌作用？
J Diabetes Complications. 1994 Jan-Mar;8(1):63-7. doi: 10.1016/1056-8727(94)90014-0.
5
[Amylin/IAPP (islet amyloid polypeptide)--physiology and clinical significance].[胰淀素/胰岛淀粉样多肽（IAPP）——生理学及临床意义]
Wien Klin Wochenschr. 1997 Jun 6;109(11):379-83.
6
Severe and disabling diabetic autonomic neuropathy: a case report.严重致残性糖尿病自主神经病变：一例报告
J Diabetes Complications. 2004 Mar-Apr;18(2):126-8. doi: 10.1016/S1056-8727(03)00004-7.
7
[Insulin-dependent diabetes].
Rev Med Liege. 1996 Nov;51(11):684-94.
8
A comparative study of microvascular complications in patients with secondary and type 1 diabetes.
Diabet Med. 1990 Nov;7(9):815-8. doi: 10.1111/j.1464-5491.1990.tb01498.x.
9
A reappraisal of current hypotheses concerning the possible roles of amylin in physiology, pathology and therapeutics.对当前关于胰岛淀粉样多肽在生理、病理及治疗方面可能作用的假说的重新评估。
Clin Sci (Lond). 1995 Jan;88(1):7-12. doi: 10.1042/cs0880007.
10
Clinical status of Ethiopian diabetic patients after 20 years of diabetes.
Diabet Med. 1991 Apr;8(3):272-6. doi: 10.1111/j.1464-5491.1991.tb01585.x.
Zotero 插件